A Study to Evaluate Circulating Cell Free Tumor DNA as a Biomarker in Sarcoma

Overview

About this study

The purpose of this study is to determine the feasibility of ctDNA detection in patients with advanced translocation-associated sarcomas.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Age 18 years old and older.
  • Advanced or metastatic bone or soft tissue sarcoma with a known translocation.
  • Evidence of disease progression or recurrence prior to initiation of systemic therapy.
  • No systemic therapy or major surgery within the past 30 days.
  • Willingness to provide blood and urine samples.
  • The absence of a second active malignancy.
  • An understanding of the protocol and its requirements, risks and discomforts.
  • Ability and willingness to sign an informed consent.

Exclusion Criteria

  • Pregnancy or lactation.
  • Inability to understand the informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brittany Siontis, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions